Figure 3.

Mean change in HbA1c (baseline to endpoint) and relative risk for all-day hypoglycemia in comparative trials of premixed analogs plus OADs in T2DM. Between treatment comparison: ^ap < 0.001; ^bp < 0.01; ^cp < 0.05. ^dCalculated value.